Paraganglioma: Clinical Trials

24 trials for Paraganglioma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 8 recruiting, 4 terminated, 3 withdrawn. 24 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 124Completed 8, Recruiting 8, Terminated 4, Withdrawn 3, Not yet recruiting 1
Phase 28Recruiting 4, Terminated 2, Completed 1, Withdrawn 1

Follow Paraganglioma: new trials by email Literature Review of Paraganglioma trials Research Report on Paraganglioma

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
211At-MABG in Adults With Advanced Neuroendocrine Cancers
1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma
Phase 1Not yet recruitingUniversity of Pennsylvania162026-12-012026-10-07
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
Phase 1RecruitingAnusha Kalbasi182025-10-072026-03-17
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
[212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma
Phase 1RecruitingNational Cancer Institute (NCI)1202025-08-192026-10-06
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)662025-02-072026-10-16
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma
Phase 1 / Phase 2RecruitingFundación de investigación HM252024-09-202026-06-04
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
ADCT-701 - Neuroendocrine Carcinomas, Neuroendocrine Tumors
Phase 1RecruitingNational Cancer Institute (NCI)702024-06-172026-11-09
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
[203Pb]VMT-α-NET, [212Pb]VMT-α-NET - Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Phase 1 / Phase 2RecruitingPerspective Therapeutics3002023-09-272026-10-13
HTL0039732 in Participants With Advanced Solid Tumours
HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion - Neoplasms, Prostatic Neoplasms, Castration-Resistant
Phase 1 / Phase 2RecruitingCancer Research UK1502023-08-022026-10-01
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
DFF332, RAD001, PDR001 - Carcinoma, Renal Cell
Phase 1TerminatedNovartis Pharmaceuticals402021-11-302026-03-03
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma
Phase 1 / Phase 2WithdrawnSue O'Dorisio2020-08-042021-06-08
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
EO2401, Nivolumab - Adrenocortical Carcinoma, Pheochromocytoma
Phase 1 / Phase 2TerminatedEnterome702020-07-232026-01-30
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Phase 1WithdrawnVanderbilt-Ingram Cancer Center2017-12-012017-09-28
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Vandetanib, 131I-mIBG - Phaeochromocytoma, Paraganglioma
Phase 1WithdrawnUniversity College, London2014-10-012015-12-21
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI) - Neuroendocrine Tumor, Paraganglioma
Phase 1 / Phase 2TerminatedUniversity of California, San Francisco3002014-06-232019-11-12
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Phase 1CompletedNational Cancer Institute (NCI)272010-10-012016-07-15
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Phase 1CompletedUniversity of Southern California192010-06-012016-06-13
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Phase 1CompletedNational Cancer Institute (NCI)272010-02-012013-05-03
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Ultratrace Iobenguane (MIBG) I 131 - Pheochromocytoma, Paraganglioma
Phase 1 / Phase 2CompletedMolecular Insight Pharmaceuticals, Inc.242007-04-012016-07-13
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Ultratrace iobenguane I 131 - Pheochromocytoma, Paraganglioma
Phase 1CompletedMolecular Insight Pharmaceuticals, Inc.242006-06-012011-10-12
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma
Phase 1CompletedMayo Clinic962004-12-012024-08-21

Showing 20 of 24. Sign in to see all of them.

Narrower conditions

Pheochromocytoma (21)  ·  Neuroendocrine Tumors (11)  ·  Carcinoma, Medullary (6)  ·  Insulinoma (6)  ·  Carcinoma, Islet Cell (5)  ·  Carcinoma, Merkel Cell (5)  ·  Glucagonoma (5)  ·  Neuroblastoma (5)  ·  Somatostatinoma (5)  ·  Carcinoma, Renal Cell (4)  ·  Gastrinoma (4)  ·  Adenoma, Islet Cell (3)  ·  Adrenocortical Carcinoma (3)  ·  Carcinoid Tumor (3)

Broader conditions

Neoplasms by Histologic Type (24)  ·  Neoplasms, Germ Cell and Embryonal (24)  ·  Neoplasms, Nerve Tissue (24)  ·  Neuroectodermal Tumors (24)  ·  Neoplasms (21)  ·  Neoplasms, Glandular and Epithelial (18)  ·  Neoplasms by Site (16)  ·  Carcinoma (15)  ·  Adenocarcinoma (14)  ·  Neuroendocrine Tumors (13)  ·  Endocrine Gland Neoplasms (12)  ·  Endocrine System Diseases (12)  ·  Digestive System Diseases (9)  ·  Digestive System Neoplasms (9)  ·  Pancreatic Diseases (9)

Interventions

Everolimus (3)  ·  gallium Ga 68 dotatate (3)  ·  3-Iodobenzylguanidine (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Temozolomide (2)  ·  lutetium Lu 177 dotatate (2)  ·  6-fluorodopamine (1)  ·  Acetates (1)  ·  Biopsy (1)  ·  Capecitabine (1)  ·  Cyclophosphamide (1)  ·  Floxuridine (1)  ·  Fluorodeoxyglucose F18 (1)  ·  High-Energy Shock Waves (1)  ·  Interleukin-13 (1)

Sponsors

National Cancer Institute (NCI) (5)  ·  Molecular Insight Pharmaceuticals, Inc. (2)  ·  Anusha Kalbasi (1)  ·  Cancer Research UK (1)  ·  Enterome (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Fundación de investigación HM (1)  ·  Mayo Clinic (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Novartis Pharmaceuticals (1)  ·  O'Dorisio, M S (1)  ·  Perspective Therapeutics (1)  ·  Sue O'Dorisio (1)  ·  University College, London (1)  ·  University of California, San Francisco (1)

Countries

United States (19)  ·  Spain (3)  ·  France (2)  ·  Italy (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Germany (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  Sweden (1)

Top investigators

Frank I Lin, M.D. (2)  ·  M. Sue O'Dorisio, MD, PhD (2)  ·  Agustin Garcia (1)  ·  Allison Betof Warner, MD, PhD (1)  ·  Antoni Ribas, MD, PhD (1)  ·  Catherine M Gordon, M.D. (1)  ·  Christina Thirlwell (1)  ·  James Yao (1)  ·  Jaydira Del Rivero, M.D. (1)  ·  Jean-Michel Paillarse (1)  ·  John R. Murren, MD (1)  ·  Jordan Berlin, M.D. (1)  ·  Julian R. Molina, M.D., Ph.D. (1)  ·  Leonard B. Saltz, MD (1)  ·  Marta Osuna Marco, PhD (1)

Results publications

PMID 20847174, PMID 23554030, PMID 25900182, PMID 29099942, PMID 29534198, PMID 31057686, PMID 31231443, PMID 34431366, PMID 39416174, PMID 40595495, PMID 42558019

NIH funding

P30CA016672 (1), R01CA300202 (1), U01CA062461 (1), U01CA097452 (1)